Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...
Eli Lilly (LLY): A Leader in Pharmaceutical Innovation and Growth
Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...
Eli Lilly announces MHRA grants marketing authorization for donanemab
Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for ...
Eastern Bank Boosts Holdings in Eli Lilly and Company (NYSE:LLY)
Eastern Bank increased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 145.8% in the 3rd quarter, according ...
Smithsonian lands big donation for America's 250th birthday celebrations
The Smithsonian Institution has received a $40 million donation to support the museum group’s celebration of America’s 250th ...
US Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds
Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
pharmaphorum3h
Lilly's Alzheimer's drug gets UK nod, but no NHS funding
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...
pharmaphorum3h
Lilly's Alzheimer's drug gets UK nod but won't be NHS-funded
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...
Lilly's weight loss drug shortage deemed over, but hurdles remain
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and ...
National Institute for Health and Care Excellence4h
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...